Literature DB >> 26374337

[Thromboprophylaxis in the critically ill : Low molecular weight heparin versus unfractionated heparin].

S Petros1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26374337     DOI： 10.1007/s00063-015-0087-y

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN： 2193-6218            Impact factor:   0.840


× No keyword cloud information.
  6 in total

1.  Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Authors:  Robert A Fowler; Nicole Mittmann; William Geerts; Diane Heels-Ansdell; Michael K Gould; Gordon Guyatt; Murray Krahn; Simon Finfer; Ruxandra Pinto; Brian Chan; Orges Ormanidhi; Yaseen Arabi; Ismael Qushmaq; Marcelo G Rocha; Peter Dodek; Lauralyn McIntyre; Richard Hall; Niall D Ferguson; Sangeeta Mehta; John C Marshall; Christopher James Doig; John Muscedere; Michael J Jacka; James R Klinger; Nicholas Vlahakis; Neil Orford; Ian Seppelt; Yoanna K Skrobik; Sachin Sud; John F Cade; Jamie Cooper; Deborah Cook
Journal:  JAMA       Date:  2014-11-26       Impact factor: 56.272

Review 2.  Thromboprophylaxis with low molecular weight heparin versus unfractionated heparin in intensive care patients: a systematic review with meta-analysis and trial sequential analysis.

Authors:  Sigrid Beitland; Irene Sandven; Lill-Kristin Kjærvik; Per Morten Sandset; Kjetil Sunde; Torsten Eken
Journal:  Intensive Care Med       Date:  2015-05-14       Impact factor: 17.440

3.  Thrombosis prophylaxis and mortality risk among critically ill adults.

Authors:  Craig M Lilly; Xinggang Liu; Omar Badawi; Christine S Franey; Ilene H Zuckerman
Journal:  Chest       Date:  2014-07       Impact factor: 9.410

4.  Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism.

Authors:  Freddy M Creekmore; Gary M Oderda; Robert C Pendleton; Diana I Brixner
Journal:  Pharmacotherapy       Date:  2006-10       Impact factor: 4.705

5.  No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.

Authors:  Kevin E Chan; Ravi I Thadhani; Franklin W Maddux
Journal:  Kidney Int       Date:  2013-05-15       Impact factor: 10.612

Review 6.  Venous thromboembolism and its prevention in critical care.

Authors:  William Geerts; Deborah Cook; Rita Selby; Edward Etchells
Journal:  J Crit Care       Date:  2002-06       Impact factor: 3.425
  6 in total
  1 in total

1.  [Acute pulmonary embolism and contraindication of anticoagulation : Bedside implantation of a new temporary vena cava inferior filter].

Authors:  S Baumann; T Becher; C Jabbour; C Fastner; K Giannakopoulos; M Behnes; T Henzler; A Alonso; S Britsch; D Loßnitzer; M Borggrefe; I Akin
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-07-25       Impact factor: 0.840
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.